-$0.23 EPS Expected for Sorrento Therapeutics, Inc. (SRNE) This Quarter
Equities analysts forecast that Sorrento Therapeutics, Inc. (NASDAQ:SRNE) will post earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Sorrento Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.25). Sorrento Therapeutics posted earnings of ($0.19) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 21.1%. The company is scheduled to report its next earnings report on Wednesday, December 6th.
On average, analysts expect that Sorrento Therapeutics will report full year earnings of ($1.10) per share for the current year. For the next fiscal year, analysts forecast that the business will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.06) to ($0.74). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Sorrento Therapeutics.
Several brokerages have weighed in on SRNE. Oppenheimer set a $7.00 target price on Sorrento Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 10th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Sorrento Therapeutics in a research report on Thursday, August 24th. Six investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $11.50.
Sorrento Therapeutics (NASDAQ:SRNE) traded up $0.05 during mid-day trading on Monday, hitting $2.35. The company had a trading volume of 775,232 shares, compared to its average volume of 830,458. The company has a current ratio of 0.54, a quick ratio of 0.54 and a debt-to-equity ratio of 0.18. Sorrento Therapeutics has a twelve month low of $1.50 and a twelve month high of $6.08.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sorrento Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.